With regulatory approval and market access being the “gate keepers” between patients and medicines, and also often one of the most cumbersome processes in our industry, there is a strong necessity for solutions that make this process more efficient and robust. Digital tools show great potential to deliver on this need yet come with many considerations and challenges. In the last of our three-part series on Digital Health, Marco Rauland shares his current view on where digital fits across the Market Access value chain, how digital solutions can add value to stakeholders involved in access discussions and key considerations for a future in which access is likely to be driven by smart algorithms.
